RT Journal Article
SR Electronic
T1 Impact of age on extra-fine particle hydrofluoroalkane beclometasone dipropionate versus fluticasone propionate outcomes in asthmatic children
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3825
VO 42
IS Suppl 57
A1 Wim van Aalderen
A1 David Price
A1 Gene Colice
A1 Paul Dorinsky
A1 Elliot Israel
A1 Richard Martin
A1 Dirkje Postma
A1 Nicholas Roche
A1 Annie Burden
A1 Elizabeth Hillyer
A1 Catherine Hutton
A1 Julie von Ziegenweidt
A1 Jonathan Grigg
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P3825.abstract
AB Background: Data on whether age influences outcomes achieved by extra-fine particle hydrofluoroalkane beclometasone dipropionate (EF HFA-BDP,QVAR®) versus fluticasone propionate (FP) in asthmatic children is limited. We compared outcomes achieved by EF HFA-BDP and FP in 5-6yr olds with those achieved in 7-11yr olds.Methods: Retrospective study using UK Clinical Practice and Optimum Patient Care Research Databases. Patients aged 5-6yrs and 7-11yrs initiating EF HFA-BDP were matched 1:1 to FP patients on baseline demographic and disease characteristics. 1yr outcomes: risk domain asthma control (RDAC; absence of: severe exacerbations, lower respiratory infection and antibiotics, out-patient attendance) ATS/ERS defined exacerbations, overall asthma control (RDAC plus short acting beta2 agonists (SABA) use) treatment success (RDAC and no change in therapy regimen) and odds of higher SABA use.Results: EF HFA-BDP matched 1:1 to FP patients; n=286:286 (5-6yr olds) and n=511:511 (7-11yr olds).Conclusion: Although the differences in treatment effects by age category were not significant, improvements in EF HFA-BDP compared with FP tend to be more noticeable in younger patients.